Canada

Who we are

  • April 5, 2022
    First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
  • April 5, 2022
    A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
  • April 5, 2022
    Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
  • April 5, 2022
    MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours
  • April 5, 2022
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
  • April 5, 2022
    Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound
  • April 5, 2022
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)